Exploring Novel Treatment Options for Interstitial Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

Anna Podolanczuk, M.D., M.S., discusses how different types of interstitial lung diseases and their main risk factors contribute to the development of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), as well as how these diseases present with common symptoms and progress over time.

Anna Podolanczuk, M.D., M.S., discusses how the mortality rates for patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) are impacted by comorbidities, including the role of autoimmune diseases in the pathophysiology of these conditions.

Anna Podolanczuk, M.D., M.S., discusses how key epidemiological trends in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), including changes in incidence and prevalence, contribute to the growing economic burden that patients with these conditions face.

Anna Podolanczuk, M.D., M.S., discusses how the differential diagnosis for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) is approached, the importance of early diagnosis and why these diseases are often misdiagnosed.

Anna Podolanczuk, M.D., M.S., discusses how biomarker testing plays a role in diagnosing idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), helping to distinguish these diseases from other respiratory conditions, as well as the role of biopsy and the histopathological features commonly seen in these diseases.

Anna Podolanczuk, M.D., M.S., discusses the key unmet needs in diagnosing idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), and how artificial intelligence (AI) could play a transformative role in enabling earlier detection of these diseases in the future.

An expert discusses the current understanding of corticosteroids in managing pulmonary fibrosis and how it has evolved in recent years, and identifies specific patient populations for whom steroids may remain a viable treatment option.

An expert discusses how nintedanib and pirfenidone differ in their mechanisms of action and efficacy in treating idiopathic pulmonary fibrosis (IPF).

An expert discusses the key side effects and contraindications associated with antifibrotic agents and how to monitor for and manage them.

An expert discusses the management plan for patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), highlighting approaches beyond pharmacotherapies.

An expert discusses the main treatment recommendations of the American Thoracic Society (ATS) guidelines for managing with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).

An expert discusses the gaps or outdated elements in the American Thoracic Society (ATS) guidelines that have been identified.

An expert discusses the treatment algorithm for patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), along with insurance coverage for the available treatment options.

An expert discusses the key unmet needs in current treatment approaches for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).

Eric Cannon, PharmD, FAMCP, discusses how the PDE4B pathway promotes inflammation and fibrosis in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) by regulating cAMP levels and fibroblast activity. Nerandomilast has shown promising anti-inflammatory and antifibrotic effects in preclinical models, with early clinical trials suggesting good tolerability and potential lung function stabilization. However, larger phase 3 trials with longer follow-up are needed to confirm efficacy, safety and impact on disease progression.